PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers.
Publication/Presentation Date
1-1-2024
Abstract
PPARγ coactivator-1α (PGC1α), as a co-activator, is known to optimize the action of several transcription factors, including androgen receptor (AR). However, the precise functions of PGC1α in prostate cancer, particularly those via the non-AR pathways, remain poorly understood. Meanwhile, our bioinformatics search suggested that PGC1α could be a direct downstream target of lysine-specific demethylase 5B (KDM5B/JARID1B/PLU1). We herein aimed to investigate how PGC1α induced prostate cancer outgrowth. Immunohistochemistry in radical prostatectomy specimens showed that the levels of PGC1α expression were significantly higher in prostatic adenocarcinoma [H-score (mean ± SD): 179.0 ± 111.6] than in adjacent normal-appearing tissue (16.7 ± 29.9,
Volume
14
Issue
9
First Page
4367
Last Page
4377
ISSN
2156-6976
Published In/Presented At
Teramoto, Y., Yang, Z., Matsukawa, T., Najafi, M. A. E., Goto, T., & Miyamoto, H. (2024). PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers. American journal of cancer research, 14(9), 4367–4377. https://doi.org/10.62347/QWZY6886
Disciplines
Medicine and Health Sciences
PubMedID
39417173
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article